RBC Capital analyst Gregory Renza downgraded Bellus Health to Sector Perform from Outperform with a price target of $14.75, down from $21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BLU:
- Bellus Health downgraded to In Line from Outperform at Evercore ISI
- GSK to acquire Bellus Health for $14.75 per share
- Bellus Health Surges after Acquisition by GSK for $2 Billion
- Bellus Health management to meet with Piper Sandler
- Bellus Health announces results from camlipixant bioavailability study